What to Expect at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

Image credit: RAVE

The inaugural 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) conference kicks off today in Chicago, Illinois, and concludes on Monday, June 10th. The previous Revolutionizing Atopic Dermatitis (RAD) conference has had an exciting upgrade to RAVE to include presentations on alopecia areata and vitiligo.

The 2024 RAVE meeting is split into 3 distinct congresses: Revolutionizing Vitiligo (ReV), Revolutionizing Alopecia Areata (RAA), and RAD. Nanette Silverberg, MD, chief of pediatric dermatology for the Mount Sinai Health System and site director of pediatric and adolescent dermatology at Mount Sinai West and Mount Sinai Beth Israel in New York, is the chair of ReV; Brett King, MD, PhD, associate professor of dermatology at the Yale School of Medicine in Connecticut, is the chair of RAA; and Jonathan Silverberg, MD, PhD, MPH, professor of dermatology and director of clinical research and contact dermatitis at the George Washington University School of Medicine and Health Sciences in Washington, DC, and the founder and chairman of the Foundation for Dermatology Education, is the chair of RAD.

Jonathan Silverberg founded the Foundation for Dermatology Education in 2020, which oversees the RAA, ReV, and RAD meetings.¹ The goal of this year’s RAVE conference is to “broaden our reach to include a deep understanding of all these conditions and learn about the latest treatment interventions to optimize patient outcomes.”²

Dermatology Times will feature interviews throughout the weekend from leaders in dermatology including:

• Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research, and Dermatology Times’ Fall 2024 Editor in Chief, who will present the sessions “How Do Approved Therapies Stack Up,” “Can We Achieve Remission With Our Current Therapies,” and numerous late-breaking abstracts.
• Jonathan Silverberg, MD, PhD, MPH, professor of dermatology and director of clinical research and contact dermatitis at the George Washington University School of Medicine and Health Sciences, who will present the sessions “Systemic Therapies Coming Soon,” “Two-for-One: Managing Atopic Comorbidities for Atopic Dermatitis,” “Battle of the Two Titans,” and numerous late-breaking abstracts.
• Nanette Silverberg, MD, chief of pediatric dermatology for the Mount Sinai Health System and site director of pediatric and adolescent dermatology at Mount Sinai West and Mount Sinai Beth Israel, who will present the sessions “Topical Therapeutics for Vitiligo,” “Excellence in Vitiligo Clinical Practice” and an atopic dermatitis late-breaking abstract.
• Melinda Gooderham, MSc, MD, FRCPC, medical director at the SKiN Centre for Dermatology in Peterborough, Ontario, Canada, who will present the sessions “New Pathways Being Explored in Atopic Dermatitis,” “Battle of the Two Titans,” and an atopic dermatitis late-breaking abstract.
• Gil Yosipovitch, MD, professor and Stiefel Chair of medical dermatology in the Dr. Phillip Frost department of dermatology and cutaneous surgery at the University of Miami, and director of the Miami Itch Center, who will present the session “State of the Art in Assessing Itch and Sleep in Atopic Dermatitis.”
• Robert Sidbury, MD, MPH, professor in the department of pediatrics at the University of Washington School of Medicine and chief of the Division of Dermatology at Seattle Children’s Hospital, who will present the session “Hot Topic: Guideline Update from Around the World.”

The inaugural 2-day conference is full of late-breaking data, informative presentations, panel discussions, live debates, and networking opportunities. Dermatology Times will cover the conference live in person, reporting on engaging sessions and conducting exclusive interviews with experts in the field. Some of the upcoming content from RAVE includes:

• Autoimmune comorbidities of atopic dermatitis
• Topical therapeutics for vitiligo
• Comparing approved therapies in atopic dermatitis
• Exploring new pathways in atopic dermatitis
• Efficacy of ritlecitinib for alopecia areata
• Assessing itch and sleep in patients with atopic dermatitis

Click here to view the full RAVE agenda.

Leading dermatology experts will discuss new data, treatments, and approaches in alopecia areata, vitiligo, and atopic dermatitis. Keep up to date with the latest in coverage from the 2024 RAVE conference and subscribe to Dermatology Times to receive daily email updates, and follow along on social media on LinkedIn, Facebook, and X.

References

1. About FDE. The Foundation for Dermatology Education. Accessed June 7, 2024. https://fde.health/about-fde
2. New in 2024. Revolutionizing Atopic Dermatitis. Accessed June 7, 2024. https://revolutionizingad.com/